Effect of Xiaflex Injection on Erectile Function in Peyronie’s Disease Patients

Overview

About this study

Peyronie’s disease is a connective tissue disorder that causes fibrosis of the tunica albuginea. It is most commonly characterized by penile curvature while erect, penile pain, and erectile dysfunction. Collagenase clostridium histolyticum (XIAFLEX) is a injectable therapy that is FDA approved for the treatment of Peyronie’s disease. The goal of this study is to evaluate and report on treatment-associated outcomes in patients with a diagnosis of Peyronie’s disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

male patients ≥18 years old with a diagnosis of Peyronie’s disease
underwent Xiaflex injection therapy
evaluated at Mayo Clinic, Rochester between January 1, 1990 and December 31, 2012
proficient in English, with at least a 5th grade reading level, in order to complete the survey

Exclusion Criteria:

None

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Landon Trost, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Landon Trost, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials